• All News
• Consumer
• Pro
• New Drugs
• Pipeline
• Clinical Trials
• FDA Alerts

Mirvetuximab Soravtansine-Gynx Beneficial for FRα-Positive Ovarian Cancer

Medically reviewed by Carmen Pope, BPharm. Last updated on Dec 7, 2023.

By Elana Gotkine HealthDay Reporter

THURSDAY, Dec. 7, 2023 -- For patients with high folate receptor α (FRα)-positive ovarian cancer, a first-in-class antibody-drug conjugate targeting FRα, mirvetuximab soravtansine-gynx (MIRV), shows a significant benefit over chemotherapy, according to a study published in the Dec. 7 issue of the New England Journal of Medicine.

Kathleen N. Moore, M.D., from the Stephenson Cancer Center Section of Gynecologic Oncology at the University of Oklahoma Health Sciences Center in Oklahoma City, and colleagues conducted a phase 3 trial to compare the efficacy and safety of MIRV to the investigator's choice of chemotherapy for treatment of platinum-resistant, high-grade serous ovarian cancer. Participants who had previously received one to three lines of therapy and had high FRα tumor expression were randomly assigned to receive MIRV or chemotherapy (paclitaxel, pegylated liposomal doxorubicin, or topotecan; 227 and 226 patients, respectively).

The researchers found that median progression-free survival was 5.62 and 3.98 months with MIRV and chemotherapy, respectively. An objective response occurred in 42.3 and 15.9 percent of participants in the MIRV and chemotherapy groups, respectively (odds ratio, 3.81). Significantly longer overall survival was seen with MIRV than chemotherapy (median, 16.46 versus 12.75 months; hazard ratio for death, 0.67). Fewer adverse events of grade 3 or higher, serious adverse events of any grade, and events leading to discontinuation occurred with MIRV than chemotherapy during the treatment period.

"Platinum-resistant ovarian cancer is a lethal disease with few efficacious, targeted treatments," the authors write. "MIRV appears to be capable of inducing responses and improving survival in patients with this disease."

The study was funded by ImmunoGen, which is developing MIRV.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted December 2023

More news resources

• FDA Medwatch Drug Alerts
• Daily MedNews
• News for Health Professionals
• New Drug Approvals
• New Drug Applications
• Drug Shortages
• Clinical Trial Results
• Generic Drug Approvals

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.